Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1/2 1Phase 1 1

Status

Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 29Neoplasms 4Renal Insufficiency 3Recurrence 3Neoplasms, Plasma Cell 3Hematologic Diseases 3Smoldering Multiple Myeloma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Immunoglobulin Light-chain Amyloidosis 2Blood Protein Disorders 2Purpura 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Nausea 1Natural Killer/T-cell Lymphoma 1Monoclonal Gammopathy of Undetermined Significance 1Macroglossia 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphadenopathy 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Hodgkin Disease 1Hepatomegaly 1Hematologic Neoplasms 1Gastrointestinal Hemorrhage 1Diarrhea 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × isatuximab × Clear all
NCT05145400 2025-09-26

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
50 enrolled
Plasma cell

Multiple Myeloma, Neoplasms

NCT04786028 2025-01-08

A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM

Canadian Myeloma Research Group

Phase 2 Active not recruiting
72 enrolled
Plasma cell

Hematologic Diseases, Multiple Myeloma, Neoplasms

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Hellenic Society of Hematology

Phase 2 Unknown
51 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡